FLOW Trial: Semaglutide and 24% Fewer Kidney Events The first dedicated GLP-1 kidney-outcomes trial in type 2 diabetes and CKD. Diabzen, [S. l.], v. 4, n. 20, p. 40–41, 2026. Disponível em: https://thediabzen.com/index.php/d/article/view/63. Acesso em: 28 jul. 2026.